Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | DLC1 |
| Gene Name: | DLC1 |
| Protein Full Name: | Rho GTPase-activating protein 7 |
| Alias: | ARHGAP7; Deleted in liver cancer 1; DLC-1; HP; P122-RhoGAP; RHG07; Rho-GTPase-activating protein 7; Rho-type GTPase-activating protein 7;Deleted in liver cancer 1 protein;Dlc-1;HP protein;StAR-related lipid transfer protein 12;StARD12;START domain-containing protein 12; StARD12; StAR-related lipid transfer (START) domain containing 12; StAR-related lipid transfer protein 12; START domain-containing protein 12 |
| Mass (Da): | 170592 |
| Number AA: | 1528 |
| UniProt ID: | P63167; B8PTI0; Q32W76; Q32W77; Q32W78; Q45XF9; Q9Y238; Q96QB1 |
| Locus ID: | 10395 |
| COSMIC ID: | DLC1 |
| Gene location on chromosome: | 8p22 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19863 |
| Percent of cancer specimens with mutations: | 1.97 |
| Gene undergoes hypermethylation: | Loss of heterozygousity and hypermethylation in 30-50% of cancers |
| Normal role description: | GTPase activating protein specific for RhoA,B,C and to a lesser extent Cdc42. Interaction with tensin proteins and localization with focal adhesion is essential for DLC1 activity. Involved in cell proliferation, migration, invasion and apoptosis. First demonstrated to act as a tumour suppressor in hepatocellular carcinoma, it was shown to be underexpressed in a variety of cancers. |